NCT01402479已完成2 期
An Open-labeled Trial of Ramipril in Patients With Migraine
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 50
- 试验地点
- 1
- 主要终点
- headache frequency
研究概览
简要总结
Physiology of migraine involving renin-angiotensin systems (RAS) has been implicated. Ramipril is a broadly-used angiotensin-converting enzyme inhibitor. The investigators attempt to test the efficacy of ramipril on the prophylaxis of migraine attacks.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 20 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with chronic migraine are included in this study. Migraineurs should be aged 20 to 70 years old with the ability to read and understand the self-report scales, including the headache diary, used in this study.
排除标准
- •Medication overuse headache are excluded in this study.
- •Treatment with other ACEI or medication that may affect ARS
- •Treatment with migraine prophylactic medications or anti-hypertensive agents including β adrenergic receptor or calcium channel blockers
- •Past history of hepatic or renal dysfunction; an abnormal electrocardiography; a psychiatric disorder; a history of substance abuse; pregnancy or lactation; use of anti-psychotics, antidepressants, or anti-anxiety drugs.
研究组 & 干预措施
ramipril
Active Comparator
open label single arm trial
干预措施: Ramipril (Drug)
结局指标
主要结局
headache frequency
时间窗: 12 week
headache days
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
4 期
Efficacy and Tolerability of Rimegepant for the Prevention of Migraine in Adults With History of Inadequate Response to Oral Preventive MedicationsMigraineNCT05518123Pfizer962
已完成
3 期
A Study to Learn About the Safety and Effects of Rimegepant to Prevent Migraine in Chinese Subjects.MigraineNCT05810038Pfizer787
已完成
4 期
Study to Assess Adverse Events When Ubrogepant Tablets in Combination With Atogepant Tablets Are Used to Treat Adult Participants With MigraineEpisodic MigraineNCT05264129AbbVie263
已完成
不适用
A Real-world, Prospective Observational Study of Rimegepant ODT for the Acute Treatment of Migraine Attacks in Adults.MigraineNCT06467370Pfizer467
已完成
4 期
A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP MedicationsMigraineNCT06701526H. Lundbeck A/S164